[go: up one dir, main page]

CL2008003062A1 - Compounds derived from spiro-conjugated pyrazoles, inhibitors of ksp kinesin activity; pharmaceutical composition comprising said compound; and use of the compound for the treatment of proliferative diseases. - Google Patents

Compounds derived from spiro-conjugated pyrazoles, inhibitors of ksp kinesin activity; pharmaceutical composition comprising said compound; and use of the compound for the treatment of proliferative diseases.

Info

Publication number
CL2008003062A1
CL2008003062A1 CL2008003062A CL2008003062A CL2008003062A1 CL 2008003062 A1 CL2008003062 A1 CL 2008003062A1 CL 2008003062 A CL2008003062 A CL 2008003062A CL 2008003062 A CL2008003062 A CL 2008003062A CL 2008003062 A1 CL2008003062 A1 CL 2008003062A1
Authority
CL
Chile
Prior art keywords
compound
inhibitors
treatment
pharmaceutical composition
pyrazoles
Prior art date
Application number
CL2008003062A
Other languages
Spanish (es)
Inventor
A Siddiqui
C Dai
U : Yang L Mansoor
L Vitharana
A Angeles
G Shipps
X Huang
C Cheng
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40254344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003062(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CL2008003062A1 publication Critical patent/CL2008003062A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos derivados de heterociclos de nitrógeno, inhibidores de la actividad de ksp kinesina; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.Compounds derived from nitrogen heterocycles, inhibitors of ksp kinesin activity; pharmaceutical composition comprising said compound; and use of the compound for the treatment of proliferative diseases.

CL2008003062A 2007-11-09 2008-10-16 Compounds derived from spiro-conjugated pyrazoles, inhibitors of ksp kinesin activity; pharmaceutical composition comprising said compound; and use of the compound for the treatment of proliferative diseases. CL2008003062A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98679907P 2007-11-09 2007-11-09

Publications (1)

Publication Number Publication Date
CL2008003062A1 true CL2008003062A1 (en) 2010-02-19

Family

ID=40254344

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003062A CL2008003062A1 (en) 2007-11-09 2008-10-16 Compounds derived from spiro-conjugated pyrazoles, inhibitors of ksp kinesin activity; pharmaceutical composition comprising said compound; and use of the compound for the treatment of proliferative diseases.

Country Status (14)

Country Link
EP (1) EP2215064A1 (en)
JP (1) JP2011503076A (en)
KR (1) KR20100075508A (en)
CN (1) CN101952255A (en)
AR (1) AR068889A1 (en)
AU (1) AU2008325025A1 (en)
CA (1) CA2702990A1 (en)
CL (1) CL2008003062A1 (en)
IL (1) IL205181A0 (en)
MX (1) MX2010004314A (en)
PE (1) PE20090968A1 (en)
TW (1) TW200922559A (en)
WO (1) WO2009061596A1 (en)
ZA (1) ZA201002700B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010004312A (en) * 2007-10-19 2010-07-05 Schering Corp Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity.
DE102008001932A1 (en) * 2008-05-21 2009-11-26 Bayer Cropscience Ag Substituted spiroisoxazolines
RU2021101430A (en) * 2014-03-20 2021-03-16 Капелла Терапьютикс, Инк. BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR CANCER TREATMENT
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5336470B2 (en) * 1971-08-09 1978-10-03
ATE448207T1 (en) * 2002-03-08 2009-11-15 Merck & Co Inc MITOTIC KINESIN INHIBITORS
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
EP1868601A4 (en) * 2005-04-07 2008-12-10 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN

Also Published As

Publication number Publication date
JP2011503076A (en) 2011-01-27
PE20090968A1 (en) 2009-07-13
WO2009061596A1 (en) 2009-05-14
ZA201002700B (en) 2010-12-29
TW200922559A (en) 2009-06-01
CN101952255A (en) 2011-01-19
MX2010004314A (en) 2010-04-30
AU2008325025A1 (en) 2009-05-14
EP2215064A1 (en) 2010-08-11
IL205181A0 (en) 2010-11-30
CA2702990A1 (en) 2009-05-14
AR068889A1 (en) 2009-12-16
KR20100075508A (en) 2010-07-02

Similar Documents

Publication Publication Date Title
CL2007002166A1 (en) Compounds derived from nitrogen heterocycles, antagonists of apoptosis protein inhibitors; its pharmaceutical compositions; and use of said compounds for the treatment of cancer.
CL2009000483A1 (en) Compounds derived from n- (pyridin-3-yl) -1,3-thiazole-5-amino-4-carboxamide, pim kinase inhibitors; pharmaceutical composition; and use for the treatment of cancer.
CL2010001415A1 (en) Compounds derived from diazacarbazole, with kinase inhibitory activity; pharmaceutical composition comprising one of the compounds; and use of the pharmaceutical composition in the preparation of medicaments for the inhibition of cell growth or the treatment of a hyperproliferative disorder
CL2008002521A1 (en) Substituted pyrazole derivative compounds, androgen receptor antagonist; pharmaceutical composition comprising said compounds; and use of the compound for the treatment of cancer.
CL2008002369A1 (en) Compounds derived from pyridin-3-yl-oxypyridin-2-yl-amino, alk5 inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.
CL2007003520A1 (en) COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE PI3 QUINASA ACTIVITY; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE FOR CANCER PROFILACTIC OR THERAPEUTIC TREATMENT.
CL2011000191A1 (en) Compounds derived from substituted fused pyrimidine, mtor inhibitors; pharmaceutical composition that includes it; and use in the treatment of cancer.
CL2007002234A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF PROLIFERATIVE DISEASES.
SV2009003307A (en) QUINAZOLINS FOR THE INHIBITION OF PDK1
SV2009003299A (en) USED DIHYDROPIRIDINE DERIVATIVES AS INHIBITORS OF PROTEIN QUINASE
CL2008003041A1 (en) Boronic acid derived compounds, proteasome inhibitors; pharmaceutical composition comprising said compound; and use of the compound for the treatment of cancer.
CL2008001705A1 (en) Compounds derived from nitrogen heterocycles; and use of the compound for the treatment of histamine h3 receptor related diseases or disorders.
CL2011001333A1 (en) Compounds derived from substituted nitrogen heterocycles, ns5a inhibitors; pharmaceutical composition; and its use for the treatment of hepatitis c.
CL2008002051A1 (en) Compounds derived from isoxazole-4-methoxy, triazole-4-methoxy or pyrazole-4-methoxy, with agonist activity of the x-farnesoid receptor (fxr); pharmaceutical composition containing them; and the use of the compounds in the preparation of drugs useful for the treatment of dyslipidemia and related diseases.
CL2008002430A1 (en) Benzenesulfonamide derived compounds, cathepsin c inhibitors; pharmaceutical composition comprising them; and its use for the treatment of copd.
CL2011002697A1 (en) Compounds derived from 3- [4- (oxo-dihydropyridin) benzyl] -1,3-oxazin-one hydrated, 11beta-hsd1 inhibitors; pharmaceutical composition comprising them; and its use in the treatment of diabetes
CL2007003557A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF THE ACTIVITY ON B-RAF; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
CL2011000454A1 (en) Compounds derived from picolinamide, pim kinase inhibitors, associated with tumorigenesis; pharmaceutical composition that includes them; and its use in the treatment of cancer.
CL2011000691A1 (en) Compounds derived from substituted nicotinamide; pharmaceutical composition that includes them; use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
CL2012003281A1 (en) Use of specific sgc stimulating and / or activating compounds; pharmaceutical formulation comprising said compounds; kit comprising the compounds, and use for the prevention and / or treatment of systematic sclerosis.
CL2008001633A1 (en) Compounds derived from pyrrolidin-3-carboxamide; pharmaceutical composition; and use as erk inhibitors for the treatment of cancer.
CL2009000426A1 (en) Compounds derived from carbocyclyl / heterocyclyl-pyridin-2-yl-urea, bacterial topoisomerase iv inhibitors; pharmaceutical composition; and its use for the treatment of bacterial infections
CL2008000418A1 (en) Use of an il-23 antagonist for the treatment of a fungal infection.
CL2008002129A1 (en) Compounds derived from substituted (1h-indazol-3-yl) -amides, kinase inhibitors; pharmaceutical composition; preparation procedure; and use of the compound for the treatment of cancer.
CL2007001435A1 (en) Phenylalanine derivative compounds; preparation process; pharmaceutical composition comprising said compound; and use of the compound as integrin inhibitors for the treatment of cancer.